Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 11/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11846648 | 0.98 | HSD11B1 (0.41) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL8677868 | 0.79 | FLT3 (0.53) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL14535324 | 0.77 | TSHR (0.60) | TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL9810645 | 0.75 | PTGS1 (0.50) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL1500290 | 0.74 | TSHR (0.58) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL322981 | 0.74 | HSD11B1 (0.42) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL544019 | 0.74 | SMN1; SMN2 (0.50) | HSD11B1TSHRALDH1A1SMN1; SMN2POLB | |
| SCHEMBL618031 | 0.74 | HSD11B1 (0.46) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL3562652 | 0.74 | ALDH1A1 (0.43) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 | |
| SCHEMBL6600300 | 0.74 | HSD11B1 (0.42) | HSD11B1TSHRPTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0462809-B1 | Method of inhibiting corrosion of copper and copper alloy with alkylbenzotriazole compositions | CALGON CORP (US) | 1994-03-23 | — | — | EP | claimed |
| EP-2590944-B1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2015-09-30 | — | — | EP | disclosed |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | RIGEL PHARMACEUTICALS, INC. (US) | 2014-10-23 | — | — | US | disclosed |
| US-8759518-B2 | Intermediates for the preparation of HMG CoA reductase inhibitors and processes for the preparation thereof | CADILA HEALTHCARE LIMITED (IN) | 2014-06-24 | — | — | US | disclosed |
| US-8575158-B2 | 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-11-05 | — | — | US | disclosed |
| US-20130158263-A1 | INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2013-06-20 | — | — | US | disclosed |
| EP-2590944-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | Actelion Pharmaceuticals Ltd. (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-05-02 | — | — | US | disclosed |
| WO-2012004722-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-01-12 | — | — | WO | disclosed |
| WO-2011104725-A2 | HMG-COA REDUCTASE INHIBITORS AND PROCESS FOR THE PREPARATION THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
| EP-0248450-A2 | Method for processing silver halide photosensitive materials and apparatus therefor | FUJI PHOTO FILM CO., LTD. (JP) | 1987-12-09 | — | — | EP | disclosed |
| US-4609619-A | CYAN COUPLER | KONISHIROKU PHOTO INDUSTRY CO., LTD. (JP) | 1986-09-02 | — | — | US | disclosed |
| EP-0136582-A2 | Developer compositions for silver halide photographic materials | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1985-04-10 | — | — | EP | disclosed |
| US-4358528-A | Formation of black-and-white silver-containing negative images by a diffusion transfer process | FUJI PHOTO FILM CO., LTD. (JP) | 1982-11-09 | — | — | US | disclosed |
| US-4355090-A | Method for making a diffusion transfer lithographic printing plates with oxazolidones | MITSUBISHI PAPER MILLS, LTD. (JP) | 1982-10-19 | — | — | US | disclosed |
| US-4351898-A | SILVER, ANTIFOGGING AGENTS | GOLDBERG RICHARD J | 1982-09-28 | — | — | US | disclosed |
| US-4309499-A | PROCESSING WITH ONE SOLUTION CONTAINING FOGGING AGENT, FOG PROMOTER, DEVELOPER, AND SOLVENT FOR SILVER HALIDE | FUJI PHOTO FILM CO., LTD. (JP) | 1982-01-05 | — | — | US | disclosed |
| US-4297430-A | WHEREIN DEVELOPMENT IS CARRIED OUT IN THE PRESENCE OF A CYCLIC IMIDE | MITSUBISHI PAPER MILLS, LTD. (JP) | 1981-10-27 | — | — | US | disclosed |
| US-4297429-A | COMPLEXING A SILVER HALIDE EMULSION AND AN O-MERCAPTOBENZOIC ACID DERIVATIVE; PHOTOLITHOGRAPHY | MITSUBISHI PAPER MILLS, LTD. (JP) | 1981-10-27 | — | — | US | disclosed |
| US-3956345-A | POLYESTER | CIBA-GEIGY AG (CH) | 1976-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158263-A1 | INTERMEDIATES FOR THE PREPARATION OF HMG COA REDUCTASE INHIBITORS AND PROCESSES FOR THE PREPARATION THEREOF | HMGCR, DHCR7, NR1H3 | HSD11B1 14/4885TSHR 2378/4885PTGS1 563/4885 |
| US-20140315884-A1 | AMPK-ACTIVATING HETEROCYCLIC COMPOUNDS AND METHODS FOR USING THE SAME | PRKAG1, PRKAG2, PRKAB1 | HSD11B1 1963/4885TSHR 1509/4885PTGS1 2657/4885 |
| US-20130109685-A1 | 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS | PTGER1, PTGDR, PTGDR2 | HSD11B1 494/4885TSHR 317/4885PTGS1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.